Thomas Holst‐Hansen

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

Filip K. Knop, Vanita R. Aroda, Ruben D do Vale et al. · The Lancet · 2023 · 379 citations

Pharmacy, Pharmacology, Pharmacotherapy +4

Spatiotemporal NF-κB dynamics encodes the position, amplitude, and duration of local immune inputs

Minjun Son, Tino Frank, Thomas Holst‐Hansen et al. · Science Advances · 2022 · 45 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity

Lua Wilkinson, Thomas Holst‐Hansen, Peter Nørkjær Laursen et al. · Obesity · 2023 · 19 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis

Xiao Wen Luah, Thomas Holst‐Hansen, Christopher Lübker · Diabetes Obesity and Metabolism · 2024 · 12 citations · Full text

Public Health, Health Behavior, Health Assessment +16

Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial

Filip K. Knop, George Kunos, Dror Dicker et al. · The Lancet Diabetes & Endocrinology · 2025 · 10 citations · Full text

Agriculture, Internal Medicine, Pharmacotherapy +8